• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

    12/18/24 8:30:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email

    Results published in two articles in Brain Stimulation

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effectively demonstrated clinically meaningful therapeutic effects on depressive symptoms and positive effects on quality of life and daily function. These findings support the use of VNS Therapy to deliver vagus nerve stimulation (VNS) in treatment-resistant depression (TRD) patients.

    A total of 493 adults with at least four documented unsuccessful attempts with antidepressant treatments participated in the unipolar cohort of the RECOVER study. At baseline, unipolar patients in the study failed more than 13 antidepressant treatments (on average) – this included, for the majority, one or more interventional therapies (e.g., transcranial magnetic stimulation, electroconvulsive therapy, or esketamine). While the RECOVER study did not meet the primary endpoint due to a strong and unforeseen response in the sham group, the active treatment arm demonstrated statistically significant and clinically meaningful improvement from the treatment arm's baseline. Further, the RECOVER study demonstrated statistically significant and clinically meaningful benefits in select secondary endpoints for this cohort. Based upon these findings and the positive effects for those who received VNS Therapy, the Company conducted additional in-depth data analyses and plans to submit three additional critical manuscripts to report on the outcomes.

    "Participants in the trial had severe, refractory depression that could not be treated effectively with other FDA-approved treatments, and most have had large portions of their lives profoundly negatively impacted by depression," said Charles Conway, MD, director of the Washington University Resistant Mood Disorders Center at Washington University School of Medicine in St. Louis. Conway is the study's lead investigator and first author of the mood outcomes article. "For this sample of markedly ill TRD participants, I am encouraged by the findings, which revealed that active VNS performed better than sham VNS treatment in all measures, and that active VNS demonstrated clinically meaningful, safe therapeutic effects. Multiple clinician, patient, and independent observer ratings separated between the active and sham unipolar arms."

    The first article, "Vagus Nerve Stimulation in Treatment-Resistant Depression: A One-Year, Randomized, Sham-Controlled Trial,"1 outlines the safety and effectiveness of adjunctive VNS Therapy in treating patients with unipolar TRD. The primary endpoint measured the difference in the percentage of time in antidepressant response between active VNS Therapy and sham VNS Therapy, with response defined as at least a 50% reduction from baseline using the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. While the predetermined p-value was p<0.023, the observed mean percentage of time in response was p=0.137.

    Analyses of secondary endpoints revealed antidepressant benefits significantly favoring active VNS Therapy as opposed to sham VNS Therapy as measured by ratings from on-site clinicians (Clinical Global Impression-Improvement, or CGI-I), patients themselves (Quick Inventory of Depressive Symptomology–Self Report, or QIDS-SR), and offsite masked raters (Quick Inventory of Depressive Symptomology–Clinical, or QIDS-C).

    Results included:

    • Participants with active VNS Therapy had significantly more percentage of time in response with CGI-I (P=0.004) and QIDS-SR (P=0.049) compared with sham VNS Therapy.
    • For percentage of time in partial response, active VNS Therapy showed significant benefit with QIDS-C (P=0.006) and CGI-I (P<0.001) compared with sham VNS Therapy. Partial response is defined as improvement of ≥30% from baseline for QIDS-C or a score of ≤3 for CGI-I.
    • No differences between treatment groups were observed in suicidal ideation and intent as measured by the S-STS2 items 6 and 8 (P=0.239).

    "The composite of the mood findings, especially in the partial response rates on multiple ratings scales, along with the low rate of adverse events, support that this device demonstrated safe antidepressant efficacy for these patients," said Conway.

    The second article, "Effects of Vagus Nerve Stimulation on Daily Function and Quality of Life in Markedly Treatment-Resistant Major Depression: Findings from a One-Year, Randomized, Sham-Controlled Trial,"3 assesses VNS Therapy's ability to improve quality of life (QoL) and daily function in patients with unipolar TRD. The results of this analysis demonstrated that adjunctive VNS Therapy provided greater improvements in QoL and daily function in patients with unipolar TRD when compared with sham VNS Therapy.

    Results included:

    • The active VNS Therapy group showed greater improvements over the sham control group as measured by the mean change in scores from baseline in the Mini-Q-LES-Q4 (P=0.050) and WPAI5 item 6 (health condition's effect on regular activities; P=0.050) used as continuous variables.
    • Time spent in a state of clinically meaningful benefit was significantly greater with active VNS Therapy compared to sham VNS Therapy, using the Q-LES-Q6 (P=0.029), Mini-Q-LES-Q (P=0.011) and WPAI item 6 (P=0.039).
    • No differences between treatment groups were observed in the mean change in score from baseline with the WHODAS7 2.0 (P=0.304) and the EQ-5D8 visual analog scale (P=0.125).

    "Adjunctive VNS Therapy improves quality of life and psychosocial function in patients with major depression who have not benefited from multiple antidepressant treatments," said A. John Rush, MD, Professor Emeritus at Duke-National University of Singapore Medical School and lead author on this article. "For these patients who are profoundly impaired, largely unemployed, and markedly treatment-resistant, depressive symptoms alone are an incomplete gauge of the clinical impact of treatments. Symptoms, function, and quality of life taken together present a more complete picture of treatment effectiveness."

    These two articles published in Brain Stimulation are the first in a series that will detail the RECOVER unipolar cohort data. Three subsequent, supportive manuscripts will feature outcomes from in-depth data analyses on select secondary endpoints. The totality of data presented in these five complementary articles will serve as the basis for LivaNova's formal request to the U.S. Centers for Medicare and Medicaid Services (CMS) for VNS Therapy coverage.

    "Patients in the RECOVER study are some of the most critically ill among those with treatment-resistant depression and they need more treatment options when existing therapies fail," said Vladimir Makatsaria, Chief Executive Officer of LivaNova. "The data from the RECOVER study and predecessor studies has shown that VNS Therapy is a safe and effective treatment option for these patients, providing hope for patients and families in similar situations who have few viable options. We look forward to sharing more of the important outcomes from the unipolar cohort with the intent to offer VNS Therapy as an important adjunctive treatment for these patients."

    RECOVER launched in 2019 as part of a Coverage with Evidence Development framework per the CMS National Coverage Determination process. For the unipolar cohort of RECOVER, enrollment was completed in March 2023, and the 12-month follow-up for those patients was completed in March 2024. No new safety issues were identified in the study.

    About RECOVER

    LivaNova's VNS Therapy™ System has been approved for the treatment of depression since earning CE Mark in 2001 and 510(k) from the U.S. Food and Drug Administration in 2005. RECOVER stands for A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.

    The largest randomized clinical study of its kind, RECOVER is examining up to 1,000 patients ages 18 or older who have unipolar or bipolar depression that is difficult to treat. The double-blind, randomized controlled study is assessing how VNS Therapy can offer patients relief from their depressive symptoms and improve quality of life. It is being carried out at up to 100 leading hospitals and medical centers across the United States.

    About VNS Therapy for Depression

    The VNS Therapy™ System, Symmetry™, is U.S. Food and Drug Administration-approved and indicated in the U.S. for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments The most commonly reported side effects are voice alteration or hoarseness, prickling or tingling in the skin, increased coughing, shortness of breath, and sore throat. Infection is the most common complication of the surgical procedure. Important safety information is available at www.livanova.com/depression/en-us/safety-information.

    References

    1. Conway CR, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1191.
    2. The Sheehan Suicidality Tracking Scale (S-STS) is a clinician-administered rating scale that tracks treatment-emergent suicidal ideation and behaviors.
    3. Rush AJ, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1187.
    4. Mini-Q-LES-Q (Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form) is a quality-of-life measure from a self-report assessing the patient's degree of enjoyment and satisfaction across seven domains as a subset of the Q-LES-Q.
    5. WPAI item 6 is a function measure from the Work Productivity and Activity Impairment (WPAI) Questionnaire.
    6. Q-LES-Q is a quality-of-life measure from a self-report assessing the patient's degree of enjoyment and satisfaction experienced over the previous seven days across 14 domains.
    7. WHODAS (World Health Organization Disability Assessment Schedule) assesses the patient's ability to perform activities in the previous month in six domains.
    8. The EuroQoL Five-Dimension Questionnaire (EQ-5D) is a generic QoL measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    About LivaNova

    LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

    Safe Harbor Statement

    This news release contains "forward-looking statements" concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the RECOVER study and the VNS Therapy™ System, Symmetry™. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241217812430/en/

    Get the next $LIVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    9/6/2023$52.00Hold
    HSBC Securities
    7/19/2023$56.00Neutral
    Robert W. Baird
    4/14/2023$48.00Neutral
    Mizuho
    More analyst ratings

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

      Top-line results at 12 months of treatment show meaningful improvement over time: Overall responder rate of 65% Overall reduction in median apnea-hypopnea index of 68% Overall reduction in median oxygen desaturation index of 68% LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and

      5/7/25 5:45:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova to Announce First-Quarter 2025 Results

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

      3/26/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • LivaNova Appoints Susan Podlogar as a New Director

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g

      10/8/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci

      4/30/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    SEC Filings

    See more
    • SEC Form IRANNOTICE filed by LivaNova PLC

      IRANNOTICE - LivaNova PLC (0001639691) (Filer)

      5/7/25 2:41:02 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by LivaNova PLC

      10-Q - LivaNova PLC (0001639691) (Filer)

      5/7/25 2:36:25 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LivaNova PLC (0001639691) (Filer)

      5/7/25 6:03:56 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LivaNova PLC

      SC 13G - LivaNova PLC (0001639691) (Subject)

      4/17/24 4:19:05 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      2/12/24 4:01:13 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      1/23/24 11:52:27 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LivaNova downgraded by Wolfe Research

      Wolfe Research downgraded LivaNova from Outperform to Peer Perform

      2/26/25 7:12:54 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on LivaNova with a new price target

      Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00

      10/4/24 7:42:40 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded LivaNova from Neutral to Outperform and set a new price target of $66.00 from $55.00 previously

      9/17/24 7:37:55 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Financials

    Live finance-specific insights

    See more
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova to Announce First-Quarter 2025 Results

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

      3/26/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

      2/25/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Innovation Officer Tezel Ahmet

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:37 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President, Global Epilepsy Bolton Stephanie converted options into 6,024 units of Ordinary Shares and covered exercise/tax liability with 2,835 units of Ordinary Shares, increasing direct ownership by 33% to 12,751 units (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:28 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Makatsaria Vladimir converted options into 9,330 units of Ordinary Shares and covered exercise/tax liability with 5,046 units of Ordinary Shares (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:18 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care